Inflammatory Breast Cancer (IBC) Registry

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Other, Procedure
Study Type: Observational
SUMMARY

This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only).

• Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis.

• Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) \[Cohort I\] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only)

• Age \> 18 years

• Able to provide informed consent

Locations
United States
Arizona
Banner - MD Anderson Cancer Center
RECRUITING
Gilbert
California
Scripps - MD Anderson Cancer Center
ACTIVE_NOT_RECRUITING
La Jolla
Colorado
Banner - MD Anderson Cancer Center - Northern Colorado
RECRUITING
Greeley
Florida
Baptist - MD Anderson Cancer Center
RECRUITING
Jacksonville
Michigan
Covenant Medical Center
ACTIVE_NOT_RECRUITING
Saginaw
Texas
M D Anderson Cancer Center
RECRUITING
Houston
MD Anderson in Katy
RECRUITING
Houston
MD Anderson League City
RECRUITING
Nassau Bay
MD Anderson in Sugar Land
RECRUITING
Sugar Land
MD Anderson in The Woodlands
RECRUITING
The Woodlands
Contact Information
Primary
Jie Willey
jwilley@mdanderson.org
713-792-3965
Time Frame
Start Date: 2007-04-17
Estimated Completion Date: 2030-04-30
Participants
Target number of participants: 1200
Treatments
Observational (biospecimen and medical data collection)
Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
Sponsors
Leads: M.D. Anderson Cancer Center
Collaborators: Texas Appropriation for Rare and Aggressive diseases, National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov